Gynecomastia in a Patient Taking Meloxicam-A Case Report.

Autor:	Rosas SL; Department of Family Medicine, Mayo Clinic Health System - Northwest Wisconsin, Menomonie, WI, USA., Deyo-Svendsen ME; Department of Family Medicine, Mayo Clinic Health System - Northwest Wisconsin, Menomonie, WI, USA., Oldfather RZ; University of Minnesota Medical School, Minneapolis, MN, USA., Phillips MR; Department of Family Medicine, Mayo Clinic Health System - Northwest Wisconsin, Menomonie, WI, USA., Israel TA; Department of Orthopedic Surgery, Mayo Clinic Health System - Northwest Wisconsin, Eau Claire, WI, USA., Weisenbeck ER; Department of Family Medicine, Mayo Clinic Health System - Northwest Wisconsin, Menomonie, WI, USA.
Jazyk:	angličtina
Zdroj:	Journal of primary care & community health [J Prim Care Community Health] 2020 Jan-Dec; Vol. 11, pp. 2150132720952622.
DOI:	10.1177/2150132720952622
Abstrakt:	Gynecomastia is benign enlargement of glandular tissue in the male breast. It occurs due to an imbalance of estrogen and testosterone. It may be unilateral or bilateral. Physiologic gynecomastia commonly occurs in infants and during puberty and is self-limited. Gynecomastia may affect up to 50% of adult men over age 50 years old and can be related to underlying medical illness or caused by certain medications. Known causative agents include anti-androgenic and estrogenic drugs. Probable agents include alcohol and anti-ulcer, psychoactive, and antiretroviral medications. Non-steroidal anti-inflammatory drugs (NSAIDs) are not commonly associated with the development of gynecomastia. This case presents an instance in which the NSAID, meloxicam, was the only identified variable in a patient who developed unilateral gynecomastia. His breast tenderness and abnormal exam resolved spontaneously within 4 weeks of cessation of meloxicam therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu